Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 526

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 526
---
762 
  
    Additional paid-in capital 
     56,139,753  
     49,393,972 
  
    Accumulated
    deficit 
     (53,644,310) 
     (44,604,479)
  
    Total
    stockholders’ equity 
     2,602,036  
     4,855,255 

    Total liabilities, and
    stockholders’ equity 
    $6,513,667  
    $8,221,552 

The
accompanying notes are an integral part of these consolidated financial statements.

F-3

bioAffinity
Technologies, Inc.

Consolidated
Statements of Operations

For
the Years Ended December 31, 2024 and 2023

    2024  
    2023 

    Net
    Revenue 
    $9,362,022  
    $2,532,499 

    Operating expenses: 

    Direct costs and expenses 
     5,983,475  
     1,740,884 
  
    Research and development 
     1,461,227  
     1,467,936 
  
    Clinical development 
     321,655  
     256,661 
  
    Selling, general and
    administrative 
     9,943,473  
     6,790,654 
  
    Depreciation
    and amortization 
     605,637  
     249,592 

    Total
    operating expenses 
     18,315,467  
     10,505,727 

    Loss
    from operations 
     (8,953,445) 
     (7,973,228)

    Other income (expense): 

    Interest income 
     17,610  
     122,131 
  
    Interest expense 
     (92,475) 
     (37,125)
  
    Other income 
     10,323  
     3,325 
  
    Other expense 
     (10,194) 
     (31,121)

    Loss
    before income taxes 
     (9,028,181) 
     (7,916,018)

    Income tax expense 
     (11,650) 
     (20,993)

    Net
    loss 
    $(